Part 3: What is the yield of genetic transformation? Genetic engineering of CAR T-cells for therapeutic applications is going through
The benefits of preventive medicine and treating early are well known and a cornerstone of the current UK healthcare system¹.
Autologous cell therapies are unique because they are made in small, individual batches, bespoke to each patient. This places new
Part 2: To what extent can T cells expand in vitro? For cell sorter developers it is critical to specify
Part 1: How many cells are needed in the therapeutic dose? This is a hard question to answer, given the
The amazing results from CAR T-cell therapies for leukaemia in 2013 (Brentjens et al., 2013; Dudley et al., 2013; Grupp